Literature DB >> 28786010

Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection.

Hyungjin Kim1, Kum Ju Chae1,2, Soon Ho Yoon1,3, Miso Kim4, Bhumsuk Keam3,4, Tae Min Kim3,4, Dong-Wan Kim3,4, Jin Mo Goo1,3, Chang Min Park5,6.   

Abstract

OBJECTIVES: To find predictors of non-diagnostic repeat biopsy specimen acquisition for mutational analysis and detection of epidermal growth factor receptor (EGFR) T790M mutation.
METHODS: We retrospectively reviewed 90 non-small cell lung cancer patients harbouring EGFR mutations who underwent repeat cone-beam CT-guided transthoracic needle biopsy. Clinical characteristics as well as biopsy-related factors were compared between patients with and without diagnostic specimen acquisition and between patients with and without T790M mutation. After univariate analysis, multivariate logistic regression analysis was performed to reveal independent predictors.
RESULTS: Diagnostic biopsy specimens for mutational test were obtained in 90% (81/90) of patients, of which 62% (50/81) possessed T790M mutation. None of the analysed variables were significantly associated with non-diagnostic specimen acquisition. For T790M detection, duration of EGFR tyrosine kinase inhibitor treatment (p = 0.066), duration of total chemotherapy (p = 0.026), tumour size (p = 0.066), and metastatic lung lesion as a biopsy target (p = 0.029) showed p values less than 0.10. Multivariate analysis revealed that target tumour size (odds ratio, 0.765; p = 0.031) was an independent predictor of T790M mutation. Metastatic lesions as biopsy targets (odds ratio, 4.194; p = 0.050) showed marginal statistical significance.
CONCLUSIONS: Non-diagnostic repeat biopsy specimen acquisition was not related to the clinical or technical factors. However, detection of T790M at repeat biopsy might be associated with smaller target tumour size and selection of metastatic lesions as biopsy targets. KEY POINTS: • Cone-beam CT-guided repeat biopsy yielded high diagnostic specimen acquisition rate. • Biopsy-related features were associated with the detection of T790M mutation. • Target tumour size was an independent predictor of the T790M detection. • Biopsy targeting metastatic lung nodules might help detect the T790M mutation.

Entities:  

Keywords:  Drug resistance; Epidermal growth factor receptor; Image-guided biopsy; Non-small-cell lung carcinoma; Protein kinase inhibitor

Mesh:

Substances:

Year:  2017        PMID: 28786010     DOI: 10.1007/s00330-017-5006-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  35 in total

1.  T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.

Authors:  Wei Li; Shengxiang Ren; Jiayu Li; Aiwu Li; Lihong Fan; Xuefei Li; Cao Zhao; Yayi He; Guanghui Gao; Xiaoxia Chen; Shuai Li; Jingyun Shi; Caicun Zhou; Ke Fei; Gerald Schmid-Bindert
Journal:  Lung Cancer       Date:  2014-03-15       Impact factor: 5.705

2.  Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.

Authors:  Juliann Chmielecki; Jasmine Foo; Geoffrey R Oxnard; Katherine Hutchinson; Kadoaki Ohashi; Romel Somwar; Lu Wang; Katherine R Amato; Maria Arcila; Martin L Sos; Nicholas D Socci; Agnes Viale; Elisa de Stanchina; Michelle S Ginsberg; Roman K Thomas; Mark G Kris; Akira Inoue; Marc Ladanyi; Vincent A Miller; Franziska Michor; William Pao
Journal:  Sci Transl Med       Date:  2011-07-06       Impact factor: 17.956

3.  Rociletinib in EGFR-mutated non-small-cell lung cancer.

Authors:  Lecia V Sequist; Jean-Charles Soria; Jonathan W Goldman; Heather A Wakelee; Shirish M Gadgeel; Andrea Varga; Vassiliki Papadimitrakopoulou; Benjamin J Solomon; Geoffrey R Oxnard; Rafal Dziadziuszko; Dara L Aisner; Robert C Doebele; Cathy Galasso; Edward B Garon; Rebecca S Heist; Jennifer Logan; Joel W Neal; Melody A Mendenhall; Suzanne Nichols; Zofia Piotrowska; Antoinette J Wozniak; Mitch Raponi; Chris A Karlovich; Sarah Jaw-Tsai; Jeffrey Isaacson; Darrin Despain; Shannon L Matheny; Lindsey Rolfe; Andrew R Allen; D Ross Camidge
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

4.  Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity.

Authors:  Hye-Suk Han; Sung-nam Lim; Jin Young An; Ki Man Lee; Kang Hyeon Choe; Ki Hyeong Lee; Seung Taik Kim; Seung-Myoung Son; Song-Yi Choi; Ho-chang Lee; Ok-Jun Lee
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

Review 5.  Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.

Authors:  Erin L Stewart; Samuel Zhixing Tan; Geoffrey Liu; Ming-Sound Tsao
Journal:  Transl Lung Cancer Res       Date:  2015-02

6.  Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.

Authors:  Maria E Arcila; Geoffrey R Oxnard; Khedoudja Nafa; Gregory J Riely; Stephen B Solomon; Maureen F Zakowski; Mark G Kris; William Pao; Vincent A Miller; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2011-01-19       Impact factor: 12.531

7.  Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications.

Authors:  Hyun Jung Yoon; Ho Yun Lee; Kyung Soo Lee; Yoon-La Choi; Myung-Ju Ahn; Keunchil Park; Jin Seok Ahn; Jong-Mu Sun; Jhingook Kim; Tae Sung Kim; Myung Jin Chung; Chin A Yi
Journal:  Radiology       Date:  2012-08-28       Impact factor: 11.105

8.  Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.

Authors:  D Zheng; X Ye; M Z Zhang; Y Sun; J Y Wang; J Ni; H P Zhang; L Zhang; J Luo; J Zhang; L Tang; B Su; G Chen; G Zhu; Y Gu; J F Xu
Journal:  Sci Rep       Date:  2016-02-12       Impact factor: 4.379

9.  Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.

Authors:  Tilak K Sundaresan; Lecia V Sequist; John V Heymach; Gregory J Riely; Pasi A Jänne; Walter H Koch; James P Sullivan; Douglas B Fox; Robert Maher; Alona Muzikansky; Andrew Webb; Hai T Tran; Uma Giri; Martin Fleisher; Helena A Yu; Wen Wei; Bruce E Johnson; Thomas A Barber; John R Walsh; Jeffrey A Engelman; Shannon L Stott; Ravi Kapur; Shyamala Maheswaran; Mehmet Toner; Daniel A Haber
Journal:  Clin Cancer Res       Date:  2015-10-07       Impact factor: 12.531

Review 10.  Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.

Authors:  Shuhang Wang; Shundong Cang; Delong Liu
Journal:  J Hematol Oncol       Date:  2016-04-12       Impact factor: 17.388

View more
  9 in total

Review 1.  Role of Image-Guided Percutaneous Needle Biopsy in the Age of Precision Medicine.

Authors:  Miyuki Sone; Shunsuke Sugawara; Yasushi Yatabe
Journal:  Curr Oncol Rep       Date:  2022-04-01       Impact factor: 5.945

2.  A new predictive scoring system based on clinical data and computed tomography features for diagnosing EGFR-mutated lung adenocarcinoma.

Authors:  Y Cao; H Xu
Journal:  Curr Oncol       Date:  2018-04-30       Impact factor: 3.677

3.  Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.

Authors:  Bing Wei; Chengzhi Zhao; Jun Li; Jiuzhou Zhao; Pengfei Ren; Ke Yang; Chi Yan; Rui Sun; Jie Ma; Yongjun Guo
Journal:  Mol Oncol       Date:  2019-04-10       Impact factor: 6.603

4.  Diagnostic Accuracy of Percutaneous Transthoracic Needle Lung Biopsies: A Multicenter Study.

Authors:  Kyung Hee Lee; Kun Young Lim; Young Joo Suh; Jin Hur; Dae Hee Han; Mi Jin Kang; Ji Yung Choo; Cherry Kim; Jung Im Kim; Soon Ho Yoon; Woojoo Lee; Chang Min Park
Journal:  Korean J Radiol       Date:  2019-08       Impact factor: 3.500

5.  Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer.

Authors:  Florian J Fintelmann; Fabian M Troschel; Martin W Kuklinski; Shaunagh McDermott; Milena Petranovic; Subba R Digumarthy; Amita Sharma; Amelie S Troschel; Melissa C Price; Lida P Hariri; Matthew D Gilman; Joanne O Shepard; Lecia V Sequist; Zofia Piotrowska
Journal:  Oncologist       Date:  2019-05-31

Review 6.  2020 Clinical Practice Guideline for Percutaneous Transthoracic Needle Biopsy of Pulmonary Lesions: A Consensus Statement and Recommendations of the Korean Society of Thoracic Radiology.

Authors:  Soon Ho Yoon; Sang Min Lee; Chul Hwan Park; Jong Hyuk Lee; Hyungjin Kim; Kum Ju Chae; Kwang Nam Jin; Kyung Hee Lee; Jung Im Kim; Jung Hee Hong; Eui Jin Hwang; Heekyung Kim; Young Joo Suh; Samina Park; Young Sik Park; Dong Wan Kim; Miyoung Choi; Chang Min Park
Journal:  Korean J Radiol       Date:  2020-11-19       Impact factor: 3.500

7.  Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.

Authors:  Eun Kyong Goag; Jung Mo Lee; Kyung Soo Chung; Song Yee Kim; Ah Young Leem; Joo Han Song; Ji Ye Jung; Moo Suk Park; Yoon Soo Chang; Young Sam Kim; Joon Chang; Eun Young Kim
Journal:  J Cancer       Date:  2018-03-02       Impact factor: 4.207

8.  Precision medicine and actionable alterations in lung cancer: A single institution experience.

Authors:  Isa Mambetsariev; Yingyu Wang; Chen Chen; Sorena Nadaf; Rebecca Pharaon; Jeremy Fricke; Idoroenyi Amanam; Arya Amini; Andrea Bild; Peiguo Chu; Loretta Erhunmwunsee; Jae Kim; Janet Munu; Raju Pillai; Dan Raz; Sagus Sampath; Lalit Vora; Fang Qiu; Lynette Smith; Surinder K Batra; Erminia Massarelli; Marianna Koczywas; Karen Reckamp; Ravi Salgia
Journal:  PLoS One       Date:  2020-02-11       Impact factor: 3.240

9.  Tissue Adequacy and Safety of Percutaneous Transthoracic Needle Biopsy for Molecular Analysis in Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis.

Authors:  Bo Da Nam; Soon Ho Yoon; Hyunsook Hong; Jung Hwa Hwang; Jin Mo Goo; Suyeon Park
Journal:  Korean J Radiol       Date:  2021-08-31       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.